...
mcrb-img

Seres Therapeutics Inc, Common Stock

MCRB

NSQ

$0.9155

-$0.01

(-1.09%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$157.23M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
2.75M
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
2.05
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.54 L
$2.05 H
$0.9155

About Seres Therapeutics Inc, Common Stock

Seres Therapeutics, Inc., a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state. The company's lead product candidate is VOWST, an oral microbiome therapeutic that has completed Phase III clinical trial for the treatment of recurrent Clostridioides difficile infection. Its product pipeline also includes SER-155, an investigational oral fermented microbiome therapeutic which is in Phase 1b clinical trials for the treatment of gastrointestinal infections, bacteremia, and graft versus host disease in immunocompromised patients including patients receiving allogeneic hematopoietic stem cell transplantation. In addition, the company engages in the development of SER-287 which is in Phase 2b and SER-301 that is in Phase 1b to treat ulcerative colitis. Further, it has license Agreement with NHSc Rx License GmbH for the therapeutic products based on the microbiome technology, which includes VOWST product candidate, which is developed for the treatment of CDI and recurrent CDI; and collaboration license agreement with Société des Produits Nestlé S.A. (Nestlé) for the development and commercialization of certain product candidates for the treatment and management of CDI and inflammatory bowel disease including UC and Crohn's disease. The company was formerly known as Seres Health, Inc. and changed its name to Seres Therapeutics, Inc. in May 2015. Seres Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameMCRBSectorS&P500
1-Week Return4.2%-2.12%-3%
1-Month Return12.48%-3.42%-0.73%
3-Month Return-18.98%-11.13%2.87%
6-Month Return21.82%-5.74%7.17%
1-Year Return-14.44%3.97%25.31%
3-Year Return-89.27%1.05%28.38%
5-Year Return-77.67%34.37%81.89%
10-Year Return-98.22%97.88%183.27%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue34.51M33.22M144.93M7.13M126.33M[{"date":"2019-12-31","value":23.81,"profit":true},{"date":"2020-12-31","value":22.92,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.92,"profit":true},{"date":"2023-12-31","value":87.16,"profit":true}]
Cost of Revenue80.14M90.57M1.73M1.00M704.00K[{"date":"2019-12-31","value":88.49,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":1.91,"profit":true},{"date":"2022-12-31","value":1.11,"profit":true},{"date":"2023-12-31","value":0.78,"profit":true}]
Gross Profit(45.64M)(57.35M)143.19M6.12M125.62M[{"date":"2019-12-31","value":-31.87,"profit":false},{"date":"2020-12-31","value":-40.05,"profit":false},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":4.28,"profit":true},{"date":"2023-12-31","value":87.73,"profit":true}]
Gross Margin(132.26%)(172.68%)98.80%85.91%99.44%[{"date":"2019-12-31","value":-133,"profit":false},{"date":"2020-12-31","value":-173.65,"profit":false},{"date":"2021-12-31","value":99.36,"profit":true},{"date":"2022-12-31","value":86.4,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Operating Expenses104.89M121.34M209.42M253.62M233.60M[{"date":"2019-12-31","value":41.36,"profit":true},{"date":"2020-12-31","value":47.85,"profit":true},{"date":"2021-12-31","value":82.57,"profit":true},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":92.11,"profit":true}]
Operating Income(71.88M)(88.13M)(64.49M)(246.49M)(107.98M)[{"date":"2019-12-31","value":-7187600000,"profit":false},{"date":"2020-12-31","value":-8813000000,"profit":false},{"date":"2021-12-31","value":-6449300000,"profit":false},{"date":"2022-12-31","value":-24649000000,"profit":false},{"date":"2023-12-31","value":-10798300000,"profit":false}]
Total Non-Operating Income/Expense2.13M(2.98M)(1.13M)(6.63M)(10.02M)[{"date":"2019-12-31","value":100,"profit":true},{"date":"2020-12-31","value":-139.8,"profit":false},{"date":"2021-12-31","value":-52.87,"profit":false},{"date":"2022-12-31","value":-311.51,"profit":false},{"date":"2023-12-31","value":-471.05,"profit":false}]
Pre-Tax Income(70.28M)(89.13M)(65.58M)(250.16M)(113.72M)[{"date":"2019-12-31","value":-7027900000,"profit":false},{"date":"2020-12-31","value":-8912700000,"profit":false},{"date":"2021-12-31","value":-6557800000,"profit":false},{"date":"2022-12-31","value":-25015700000,"profit":false},{"date":"2023-12-31","value":-11372400000,"profit":false}]
Income Taxes(6.04M)(2.67M)(4.08M)3.67M14.95M[{"date":"2019-12-31","value":-40.38,"profit":false},{"date":"2020-12-31","value":-17.88,"profit":false},{"date":"2021-12-31","value":-27.31,"profit":false},{"date":"2022-12-31","value":24.53,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Income After Taxes(64.24M)(86.45M)(61.50M)(253.82M)(128.67M)[{"date":"2019-12-31","value":-6424400000,"profit":false},{"date":"2020-12-31","value":-8645400000,"profit":false},{"date":"2021-12-31","value":-6149600000,"profit":false},{"date":"2022-12-31","value":-25382400000,"profit":false},{"date":"2023-12-31","value":-12867010500,"profit":false}]
Income From Continuous Operations(70.28M)(89.13M)(65.58M)(250.16M)(141.27M)[{"date":"2019-12-31","value":-7027900000,"profit":false},{"date":"2020-12-31","value":-8912700000,"profit":false},{"date":"2021-12-31","value":-6557800000,"profit":false},{"date":"2022-12-31","value":-25015700000,"profit":false},{"date":"2023-12-31","value":-14127200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(64.24M)(86.45M)(61.50M)(253.82M)(113.72M)[{"date":"2019-12-31","value":-6424400000,"profit":false},{"date":"2020-12-31","value":-8645400000,"profit":false},{"date":"2021-12-31","value":-6149600000,"profit":false},{"date":"2022-12-31","value":-25382400000,"profit":false},{"date":"2023-12-31","value":-11372400000,"profit":false}]
EPS (Diluted)(1.31)(1.15)(0.72)(2.34)(0.90)[{"date":"2019-12-31","value":-131,"profit":false},{"date":"2020-12-31","value":-115,"profit":false},{"date":"2021-12-31","value":-72,"profit":false},{"date":"2022-12-31","value":-234,"profit":false},{"date":"2023-12-31","value":-90,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

MCRB
Cash Ratio 1.03
Current Ratio 1.12

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

MCRB
ROA (LTM) -9.70%
ROE (LTM) -1556.28%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

MCRB
Debt Ratio Lower is generally better. Negative is bad. 0.87
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. 0.13

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

MCRB
Trailing PE NM
Forward PE NM
P/S (TTM) 1.24
P/B 6.57
Price/FCF NM
EV/R 1.46
EV/Ebitda NM
PEG NM

FAQs

What is Seres Therapeutics Inc share price today?

Seres Therapeutics Inc (MCRB) share price today is $0.9155

Can Indians buy Seres Therapeutics Inc shares?

Yes, Indians can buy shares of Seres Therapeutics Inc (MCRB) on Vested. To buy Seres Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in MCRB stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Seres Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of Seres Therapeutics Inc (MCRB) via the Vested app. You can start investing in Seres Therapeutics Inc (MCRB) with a minimum investment of $1.

How to invest in Seres Therapeutics Inc shares from India?

You can invest in shares of Seres Therapeutics Inc (MCRB) via Vested in three simple steps:

  • Click on Sign Up or Invest in MCRB stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Seres Therapeutics Inc shares
What is Seres Therapeutics Inc 52-week high and low stock price?

The 52-week high price of Seres Therapeutics Inc (MCRB) is $2.05. The 52-week low price of Seres Therapeutics Inc (MCRB) is $0.54.

What is Seres Therapeutics Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Seres Therapeutics Inc (MCRB) is

What is Seres Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Seres Therapeutics Inc (MCRB) is 6.57

What is Seres Therapeutics Inc dividend yield?

The dividend yield of Seres Therapeutics Inc (MCRB) is 0.00%

What is the Market Cap of Seres Therapeutics Inc?

The market capitalization of Seres Therapeutics Inc (MCRB) is $157.23M

What is Seres Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of Seres Therapeutics Inc is MCRB

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top